Suchergebnisse - "Galstyan, Gagik R"

PubPharm (12)

1

Real-World Effectiveness and Safety of Insulin Glargine 300 U/mL in Insulin-Naïve People with Type 2 Diabetes : the ATOS Study

enthalten in: Diabetes therapy : research, treatment and education of diabetes and related disorders | 2022

von Galstyan, G. | Tirosh, A. | Vargas-Uricoechea, H. | +5

2

Real-World Effectiveness and Safety of Insulin Glargine 300 U/mL in Insulin-Naïve People with Type 2 Diabetes: the ATOS Study

enthalten in: Diabetes therapy | 2022

von Galstyan, G. | Tirosh, A. | Vargas-Uricoechea, H. | +5

3

Real-World Effectiveness and Safety of Insulin Glargine 300 U/mL in Insulin-Naïve People with Type 2 Diabetes: the ATOS Study

enthalten in: Diabetes therapy | 2022

von Galstyan, G. | Tirosh, A. | Vargas-Uricoechea, H. | +5

4

Real-World Effectiveness and Safety of Insulin Glargine 300 U/mL in Insulin-Naïve People with Type 2 Diabetes: the ATOS Study

enthalten in: Diabetes therapy | 2022

von Galstyan, G. | Tirosh, A. | Vargas-Uricoechea, H. | +5

5

Lifestyle modification program, LIFE is LIGHT, in patients with type 2 diabetes mellitus and obesity : Results from a 48-week, multicenter, non-randomized, parallel-group, open-label study

enthalten in: Obesity science & practice | 2021

von Galstyan, G. | Valeeva, F. | Motkova, S. | +7

6

Management of patients with diabetes and obesity in the COVID-19 era : Experiences and learnings from South and East Europe, the Middle East, and Africa

enthalten in: Diabetes research and clinical practice | 2021

von Giorgino, F. | Bhana, S. | Czupryniak, L. | +8

7

Lifestyle modification program, LIFE is LIGHT, in patients with type 2 diabetes mellitus and obesity : Results from a 48‐week, multicenter, non‐randomized, parallel‐group, open‐label study

enthalten in: Obesity Science & Practice | 2021

von Galstyan, G. | Valeeva, F. | Motkova, S. | +7

8

COVID-19 pandemic and endocrinopathies

enthalten in: Problemy endokrinologii | 2020

von Mokrysheva, N. | Galstyan, G. | Kirzhakov, M. | +3

9

Glycaemic benefit of iGlarLixi in insulin-naive type 2 diabetes patients with high HbA1c or those with inadequate glycaemic control on two oral antihyperglycaemic drugs in the LixiLan-O randomized trial

enthalten in: Diabetes, obesity & metabolism | 2019

von Davies, M. | Russell-Jones, D. | Barber, T. | +6

10

Glycaemic benefit of iGlarLixi in insulin‐naive type 2 diabetes patients with high HbA1c or those with inadequate glycaemic control on two oral antihyperglycaemic drugs in the LixiLan‐O randomized trial

enthalten in: Diabetes, Obesity and Metabolism | 2019

von Davies, M. | Russell‐Jones, D. | Barber, T. | +6